Iodine-131 tositumomab

BioDrugs

Volumn 17, Issue 4, 2003, Pages 290-295

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; TOSITUMOMAB I 131;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CHRONIC LYMPHATIC LEUKEMIA; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOMODULATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0041441188     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317040-00009     Document Type: Review

References (28)

1. Corixa Corporation, GlaxoSmithKline. Corixa Corporation and GlaxoSmithKline enter into license and supply agreement for Bexxar™ therapy in Canada [online]. Media Release: 28 May 2003. Available from URL: http://www.corixa.com
2. Kostakoglu L, Leonard JP, Coleman M, et al. Extent of disease impacts the effective half-life of iodine in I-131 tositumomab in non-Hodgkin's lymphoma. Blood 1999 Nov; 94 Suppl. 1: 90, Pt 1
3. Gupta NK, Cao TM, French JN, et al. Pilot study of Bexxar™ in advanced previously heavily treated refractory chronic lymphocytic leukemia. Blood 2001 Nov; 98: 290, Pt 2
4. Coulter Pharmaceutical Inc. Coulter Pharmaceutical announces interim data from phase III investigational trial of Bexxar™: the company closes phase III enrollment. Media Release: [2 pages], 13 May 1998
5. Press O, Eary J, Liu S, et al. A phase I/II trial of high dose iodine-131-anti-B1 (anti-cd20) monoclonal antibody, etoposide, cyclophosphamide, and autologous stem cell transplantation for patients with relapsed B-cell lymphomas. 34th Annual Meeting of the American Society of Clinical Oncology 17: 3, 16 May 1998
6. Vose JM, Zelenetz AD, Rohatiner A, et al. Iodine-131 tositumomab for patients with follicular non-Hodgkin's lymphoma: overall clinical trial experience by histology. Blood 1999 Nov; 94 Suppl. 1: 89, Pt 1
7. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine-131 tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000 Aug; 96: 1259-66
8. Bennett JM, Zelenetz AD, Press OW, et al. Incidence of myelodysplastic syndromes and acute myeloid leukemia in patients with low-grade non-Hodgkin's lymphoma treated with Bexxar™. Blood 2001 Nov; 98: 335, Pt 1
9. Zelenetz AD, Vose JM, Knox S, et al. Iodine-131 tositumomab for patients with transformed low-grade non-Hodgkin's lymphoma: overall clinical trial experience. Blood 1999 Nov; 94 Suppl. 1: 632, Pt 1
10. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131 tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000 Nov; 96: 2934-42
11. Corixa Corporation. Durable responses reported with Bexxar™ alone or in sequential therapy for low-grade non-Hodgkin's lymphoma [online]. Media Release: [4 pages], 11 Dec 2001. Available from URL: http://www.corixa.com
12. Corixa Corporation. Analysis of long-term response population from Bexxar™ clinical trials presented at ASCO [online] Media Release: 31 May 2003. Available from URL: http://www.corixa.com
13. Kaminski MS, Gribbin T, Estes J, et al. I-131 anti-B1 antibody for previously untreated follicular lymphoma: clinical and molecular remissions. 34th Annual Meeting of the American Society of Clinical Oncology 17: 2, 16 May 1998
14. Coulter Pharmaceutical compares Bexxar™ to unlabeled monoclonal antibody for treatment of non-Hodgkin's lymphoma. Media Release: [3 pages], 21 Oct 1997
15. Coulter Pharmaceutical Inc. Annual Report 1998: the Bexxar™ alternative. Company Communication: 4-5, 1998
16. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001 Oct; 19: 3918-3928
17. Coulter Pharmaceutical Inc. Coulter Pharmaceutical announces positive phase III investigational trial results for Bexxar™ in non-Hodgkin's lymphoma. Media Release: [2 pages], 20 Oct 1998
18. Wahl RL, Tidmarsh G, Kroll S, et al. Successful re-treatment of non-Hodgkin's lymphoma with iodine-131 anti-B1 antibody. 34th Annual Meeting of the American Society of Clinical Oncology 17: 40, 16 May 1998
19. Coulter Pharmaceutical Inc. Coulter Pharmaceutical reports follow-up data on 432 patients treated with Bexxar™. Media Release: [3 pages], 8 Jun 1999. Available from URL: http://www.coulter.com
20. Coulter Pharmaceuticals Inc. Annual Report 1998: letter from Michael F Bigham (President and Chief Executive Officer.). Company Communication: 7-9, 1998
21. Coulter Pharmaceutical Inc, SmithKline Beecham. Coulter Pharmaceutical and SmithKline Beecham announce promising results with Bexxar™ in NHL patients who previously failed rituximab treatment [online]. Media Release: [4 pages], 4 Dec 2000. Available from URL: http://www.coulterpharm.com
22. Horning SJ, Lucas JB, Younes A, et al. Iodine-131 tositumomab for non-Hodgkin's lymphoma patients who progressed after treatment with rituximab: results of a multicenter phase II study. Blood 2000 Nov; 96: 508 (plus oral presentation), Pt 1
23. Leonard JP, Frenette G, Dillman RO, et al. Interim saftey and efficacy results of Bexxar™ in a large multicenter expanded access study. Blood 2001 Nov; 98: 133, Pt 1
24. GlaxoSmithKline, Corixa Corporation. Bexxar™ therapy evaluated in treating low-grade non-Hodgkin's lymphoma in both academic and community settings study presented at the American Society of Clinical Oncology Annual Meeting [online]. Media Release: [4 pages], 14 May 2001. Available from URL: http://www.glaxosmithkline.com
25. Wahl R, Kaminski M, Zelenetz A, et al. Each subsequent therapy results in diminishing response rate and duration of response in low grade or transformed low grade non-Hodgkin's lymphoma. 37th Annual Meeting of the American Society of Clinical Oncology 20: 292, Pt 1, 12 May 2001
26. Kaminski M, Estes J, Regan D, et al. Retreatment with Bexxar™ (tositumomab and iodine-131 tositumomab) for patients with low-grade or transformed low-grade non-Hodgkin's lymphoma. 37th Annual Meeting of the American Society of Clinical Oncology 20: 285, Pt 1, 12 May 2001
27. Coulter Pharmaceutical Inc. Coulter Pharmaceutical reports clinical data from a phase I/II investigational trial of high-dose Bexxar™ in combination with chemotherapy for non-Hodgkin's lymphoma. Media Release: [3 pages], 19 May 1998
28. Coulter Pharmaceutical, Inc., SmithKline Beecham. Coulter Pharmaceutical and SmithKline Beecham announce combined results of clinical trials with Bexxar™ in various types of NHL [online]. Media Release: [3 pages], 15 Dec 1999. Available from URL: http://www.sb.com/